Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to detail his many portfolio moves. DOGE Stimulus Checks ...

Jefferies lowered the firm’s price target on Vertex (VERX) to $48 from $62 and keeps a Buy rating on the shares. The company’s results beat on ...

Vertex Minerals’ (ASX:VTX) share price fell 3.6% in lunchtime trades to 26cps, even as the company prepares for its first ...

Stifel analyst Brad Reback downgraded Vertex (VERX) to Hold from Buy with a price target of $31, down from $58. The company posted solid Q4 ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsJoe Crivelli – Vice President of ...

Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced the ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...

Arc’teryx unveils its 2025 footwear lineup, featuring the Norvan LD 4, Vertex Speed, and Konseal, designed to enhance ...

It's not enough to go far or even fast. The upcoming Arc'teryx Vertex Speed trail running shoe can also travel high.